Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
to the foundation. Under certain circumstances, scholarship holders may receive the following additional benefits: To prepare for the stay in Germany, the DAAD pays for a language course before the start of the study
-
well as professional and personal support. The scholarship holders are supported in their personal development with a large number of offers. This includes soft skill seminars and language courses as well as summer
-
of aerospace and to act as a centre of research, development and training. The Munich Aerospace unites 4 entities under one institutional roof: the TUM (Technical University Munich), the UniBwM (University
-
well as key skills development. Target Group particularly gifted German and international doctoral candidates from any discipline completing promising doctoral dissertations at a German higher education
-
Service' (DAAD). DLR is Germany’s national research centre for aeronautics and space. Its extensive research and development work in Aeronautics, Space, Energy and Transport is integrated into national and
-
advantageous. These projects provide an excellent opportunity to develop expertise in immunometabolism, aging research, and cutting-edge genomic techniques. The candidates will gain experience with advanced
-
research spectrum covers a unique range. Institute of Material and Process Design The Institute of Material and Process Design is dedicated to the sustainable and ecological development of innovative
-
project: Proper division of the genomic material is fundamental for cell homeostasis. Although cells have developed a plethora of mechanisms to ensure error-free division, mistakes during mitosis are common
-
closely with architects, engineers, biologists, and chemists at the University of Stuttgart and the University of Freiburg. The research focuses on the conception, development, and evaluation of bio
-
/progenitor cells. A clinically active p300/CREBBP inhibitor is currently in development and is expected to enter clinical trials in late 2026. PhD project: Targeting p300/CREBBP to Enhance Interferon Signaling